TKNO vs. CODX, AXDX, DMTK, ACHV, VNRX, ABIO, ICCC, AWH, OCX, and TRIB
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include Co-Diagnostics (CODX), Accelerate Diagnostics (AXDX), DermTech (DMTK), Achieve Life Sciences (ACHV), VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), and Trinity Biotech (TRIB). These companies are all part of the "medical" sector.
Alpha Teknova (NASDAQ:TKNO) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 2.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Co-Diagnostics has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a net margin of -97.85% compared to Co-Diagnostics' net margin of -582.36%. Alpha Teknova's return on equity of -38.24% beat Co-Diagnostics' return on equity.
Alpha Teknova currently has a consensus price target of $15.00, indicating a potential upside of 710.81%. Co-Diagnostics has a consensus price target of $2.00, indicating a potential upside of 49.25%. Given Alpha Teknova's stronger consensus rating and higher probable upside, equities analysts clearly believe Alpha Teknova is more favorable than Co-Diagnostics.
Co-Diagnostics received 266 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 33.33% of users gave Alpha Teknova an outperform vote.
Alpha Teknova has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.85, meaning that its stock price is 185% less volatile than the S&P 500.
In the previous week, Alpha Teknova's average media sentiment score of 1.00 beat Co-Diagnostics' score of 0.00 indicating that Alpha Teknova is being referred to more favorably in the media.
Summary
Alpha Teknova beats Co-Diagnostics on 11 of the 17 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
